Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Peritoneal Cancer - Global Drug Pipeline Analysis and Competitive Landscape, 2026 | 75+ Therapies Drive ADCs, Targeted Therapy, and Immunotherapy Growth Opportunities

globenewswire.com
ABBV AbbVie is mentioned as a key company with a pipeline product (ABBV-901) in the peritoneal cancer drug development landscape. The article does not provide specific sentiment on AbbVie's performance or prospects. AZN AstraZeneca is listed as a key company with a late-stage product (AZD5335) in peritoneal cancer development. The article does not offer specific sentiment regarding AstraZeneca's performance or outlook. CELH Celldex Therapeutics is identified as a key company in the peritoneal cancer drug pipeline. The article does not provide specific sentiment or details about their performance. INCY Incyte Corporation is mentioned as a key company with a pipeline product (INCB0123667) in peritoneal cancer research. The article does not offer specific sentiment on the company. REGN Regeneron Pharmaceuticals is listed as a key company with a pipeline product (REGN5668) in peritoneal cancer development. The article does not provide specific sentiment on the company's prospects.

Peritoneal Cancer - Global Drug Pipeline Analysis and Competitive Landscape, 2026 | 75+ Therapies Drive ADCs, Targeted Therapy, and Immunotherapy Growth Opportunities Dublin, Oct. 01, 2026 (GLOBE NEWSWIRE) -- "Peritoneal Cancer - Pipeline Insight, 2026" has been added to ResearchAndMarkets.com's offering.

The "Peritoneal Cancer - Pipeline Insight, 2026" report delivers a comprehensive global analysis of the peritoneal cancer pipeline, covering 60+ companies and 75+ pipeline drugs across clinical and nonclinical development. It evaluates active and inactive candidates by development stage, product type, route of administration, and molecule type. The report also examines clinical studies, mechanisms of action, regulatory designations, licensing agreements, collaborations, funding, mergers and acquisitions, and other product development activities influencing the peritoneal cancer therapeutics market.

Geographic Coverage

Peritoneal Cancer Overview

Peritoneal cancer includes primary malignancies originating in the abdominal mesothelium and secondary disease resulting from tumor dissemination into the peritoneal cavity. Primary peritoneal cancer includes histological classifications such as extraovarian primary peritoneal carcinoma (EOPPC), serous surface papillary carcinoma, papillary serous carcinoma of the peritoneum, extraovarian Mullerian adenocarcinoma, and normal-sized ovarian carcinoma syndrome.

Common clinical presentations include abdominal bloating, distension, nausea, indigestion, anorexia, weight loss, fatigue, constipation, and abdominal or back pain. Abdominal distension, pain, ascites, and a palpable abdominal mass are frequently reported.

Disease progression involves tumor cell detachment from primary cancers, including ovarian, colorectal, and gastric malignancies, followed by circulation through peritoneal fluid and adhesion to the mesothelium. Tumor cells subsequently invade surrounding tissues, stimulate angiogenesis, and establish metastatic deposits. Dissemination may also occur through lymphatic pathways or during surgical procedures.

Diagnosis combines laboratory testing, imaging, cytology, and histopathology. Investigations may include complete blood count, comprehensive metabolic panel, coagulation studies, serum albumin, and tumor markers such as CA-125, carcinoembryonic antigen, CA 19-9, alpha-fetoprotein, and CA 15-3. Ultrasound, computed tomography, magnetic resonance imaging, and PET-CT support the evaluation of masses, ascites, peritoneal dissemination, and metastases. Paracentesis, biopsy, laparoscopy, laparotomy, and immunohistochemistry may be used for definitive characterization.

Current peritoneal cancer treatment uses multimodal strategies that may include cytoreductive surgery, hyperthermic intraperitoneal chemotherapy, systemic chemotherapy, targeted therapy, and immunotherapy. Intraperitoneal approaches include early postoperative intraperitoneal chemotherapy, pressurized intraperitoneal aerosol chemotherapy, and bidirectional/neoadjuvant intraperitoneal and systemic chemotherapy. Agents used across treatment settings include mitomycin C, cisplatin, oxaliplatin, 5-fluorouracil, taxanes, PARP inhibitors such as olaparib, and checkpoint inhibitors.

Peritoneal Cancer Pipeline Highlights

The report assesses commercial and clinical opportunities across Phase III, Phase II, Phase I, Pre-clinical, and Discovery stage programs. It identifies research trends, unmet needs, novel technologies, clinical trial activity, and emerging therapeutic strategies intended to improve outcomes for patients with peritoneal cancer.

Selected Emerging Peritoneal Cancer Drugs

Therapeutic Segmentation

Pipeline products are assessed by clinical stage, including late-stage products in Phase III, mid-stage products in Phase II, Early-stage product programs in Phase I, Pre-clinical and Discovery stage candidates, and discontinued or inactive assets. Routes of administration include oral, intravenous, subcutaneous, parenteral, and topical delivery. Molecule types include recombinant fusion proteins, small molecule therapies, monoclonal antibodies, peptides, polymers, and gene therapies. Product strategies are categorized as Mono, Combination, or Mono/Combination.

Key Companies

Companies covered include AstraZeneca, RemeGen Co., Ltd., Volastra Therapeutics, Inc., SystImmune Inc., Instil Bio, OncoC4, Inc., AbbVie, Rhizen Pharmaceuticals SA, Toray Industries, Inc, Precigen, Inc, Celldex Therapeutics, Mersana Therapeutics, Incyte Corporation, Transgene, Bio-Path Holdings, Inc., Arsenal Biosciences, Inc., Novakand Pharma AB, Regeneron Pharmaceuticals, Artios Pharma Ltd, 23andMe, Inc., Avenzo Therapeutics, Inc., Medicenna Therapeutics, Inc., TORL Biotherapeutics, LLC, CanariaBio Inc., and Shanghai Jiaolian Drug Research and Development Co., Ltd.

Key Pipeline Products

Featured candidates include AZD5335, RC88, Sovilnesib, BL-M17D1, ITIL-306, AI-061, ABBV-901, RP12146, TRK-950, PRGN-3005, CDX-585, XMT-1660, INCB0123667, TG4050, BP1001-A, AB-1015, KAND567, REGN5668, ART0380, 23ME-00610, AVZO-021, MDNA11, TORL-1-23, Oregovomab, and B013.

Report Scope

Key Topics Covered:

Introduction

Executive Summary

Peritoneal Cancer: Overview

Pipeline Therapeutics

Therapeutic Assessment

Peritoneal Cancer- Analytical Perspective

Late Stage Products (Phase III)

AZD5335: AstraZeneca

Mid Stage Products (Phase II)

RC88: RemeGen Co., Ltd.

Early Stage Products (Phase I)

BL-M17D1: SystImmune Inc.

Preclinical and Discovery Stage Products

Inactive Products

Peritoneal Cancer Key Companies

Peritoneal Cancer Key Products

Peritoneal Cancer- Unmet Needs

Peritoneal Cancer- Market Drivers and Barriers

Peritoneal Cancer- Future Perspectives and Conclusion

Peritoneal Cancer Analyst Views

Appendix

List of Tables [12]

List of Figures [12]

A selection of companies mentioned in this report includes, but is not limited to:

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/g9mnwm

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.